197 related articles for article (PubMed ID: 20053923)
1. Influence of cell background on pharmacological rescue of mutant CFTR.
Pedemonte N; Tomati V; Sondo E; Galietta LJ
Am J Physiol Cell Physiol; 2010 Apr; 298(4):C866-74. PubMed ID: 20053923
[TBL] [Abstract][Full Text] [Related]
2. Phenylglycine and sulfonamide correctors of defective delta F508 and G551D cystic fibrosis transmembrane conductance regulator chloride-channel gating.
Pedemonte N; Sonawane ND; Taddei A; Hu J; Zegarra-Moran O; Suen YF; Robins LI; Dicus CW; Willenbring D; Nantz MH; Kurth MJ; Galietta LJ; Verkman AS
Mol Pharmacol; 2005 May; 67(5):1797-807. PubMed ID: 15722457
[TBL] [Abstract][Full Text] [Related]
3. F508del-cystic fibrosis transmembrane regulator correctors for treatment of cystic fibrosis: a patent review.
Yang H; Ma T
Expert Opin Ther Pat; 2015; 25(9):991-1002. PubMed ID: 25971311
[TBL] [Abstract][Full Text] [Related]
4. Elexacaftor Mediates the Rescue of F508del CFTR Functional Expression Interacting with MSD2.
Bongiorno R; Ludovico A; Moran O; Baroni D
Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37629017
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and structure-activity relationship of aminoarylthiazole derivatives as correctors of the chloride transport defect in cystic fibrosis.
Pesce E; Bellotti M; Liessi N; Guariento S; Damonte G; Cichero E; Galatini A; Salis A; Gianotti A; Pedemonte N; Zegarra-Moran O; Fossa P; Galietta LJ; Millo E
Eur J Med Chem; 2015 Jun; 99():14-35. PubMed ID: 26041577
[TBL] [Abstract][Full Text] [Related]
6. Differential sensitivity of the cystic fibrosis (CF)-associated mutants G551D and G1349D to potentiators of the cystic fibrosis transmembrane conductance regulator (CFTR) Cl- channel.
Cai Z; Taddei A; Sheppard DN
J Biol Chem; 2006 Jan; 281(4):1970-7. PubMed ID: 16311240
[TBL] [Abstract][Full Text] [Related]
7. Unravelling the Regions of Mutant F508del-CFTR More Susceptible to the Action of Four Cystic Fibrosis Correctors.
Amico G; Brandas C; Moran O; Baroni D
Int J Mol Sci; 2019 Nov; 20(21):. PubMed ID: 31683989
[TBL] [Abstract][Full Text] [Related]
8. Mutation-specific potency and efficacy of cystic fibrosis transmembrane conductance regulator chloride channel potentiators.
Caputo A; Hinzpeter A; Caci E; Pedemonte N; Arous N; Di Duca M; Zegarra-Moran O; Fanen P; Galietta LJ
J Pharmacol Exp Ther; 2009 Sep; 330(3):783-91. PubMed ID: 19491324
[TBL] [Abstract][Full Text] [Related]
9. Trimethylangelicin promotes the functional rescue of mutant F508del CFTR protein in cystic fibrosis airway cells.
Favia M; Mancini MT; Bezzerri V; Guerra L; Laselva O; Abbattiscianni AC; Debellis L; Reshkin SJ; Gambari R; Cabrini G; Casavola V
Am J Physiol Lung Cell Mol Physiol; 2014 Jul; 307(1):L48-61. PubMed ID: 24816489
[TBL] [Abstract][Full Text] [Related]
10. Correctors and Potentiators Rescue Function of the Truncated W1282X-Cystic Fibrosis Transmembrane Regulator (CFTR) Translation Product.
Haggie PM; Phuan PW; Tan JA; Xu H; Avramescu RG; Perdomo D; Zlock L; Nielson DW; Finkbeiner WE; Lukacs GL; Verkman AS
J Biol Chem; 2017 Jan; 292(3):771-785. PubMed ID: 27895116
[TBL] [Abstract][Full Text] [Related]
11. Discovery of a picomolar potency pharmacological corrector of the mutant CFTR chloride channel.
Pedemonte N; Bertozzi F; Caci E; Sorana F; Di Fruscia P; Tomati V; Ferrera L; Rodríguez-Gimeno A; Berti F; Pesce E; Sondo E; Gianotti A; Scudieri P; Bandiera T; Galietta LJV
Sci Adv; 2020 Feb; 6(8):eaay9669. PubMed ID: 32128418
[TBL] [Abstract][Full Text] [Related]
12. Potentiators of Defective ΔF508-CFTR Gating that Do Not Interfere with Corrector Action.
Phuan PW; Veit G; Tan JA; Finkbeiner WE; Lukacs GL; Verkman AS
Mol Pharmacol; 2015 Oct; 88(4):791-9. PubMed ID: 26245207
[TBL] [Abstract][Full Text] [Related]
13. Discovery and SAR of 4-aminopyrrolidine-2-carboxylic acid correctors of CFTR for the treatment of cystic fibrosis.
Scanio MJC; Searle XB; Liu B; Koenig JR; Altenbach RJ; Gfesser GA; Bogdan A; Greszler S; Zhao G; Singh A; Fan Y; Swensen AM; Vortherms T; Manelli A; Balut C; Gao W; Yong H; Schrimpf M; Tse C; Kym P; Wang X
Bioorg Med Chem Lett; 2022 Sep; 72():128843. PubMed ID: 35688367
[TBL] [Abstract][Full Text] [Related]
14. New pharmacological approaches for cystic fibrosis: promises, progress, pitfalls.
Bell SC; De Boeck K; Amaral MD
Pharmacol Ther; 2015 Jan; 145():19-34. PubMed ID: 24932877
[TBL] [Abstract][Full Text] [Related]
15. Antihypertensive 1,4-dihydropyridines as correctors of the cystic fibrosis transmembrane conductance regulator channel gating defect caused by cystic fibrosis mutations.
Pedemonte N; Diena T; Caci E; Nieddu E; Mazzei M; Ravazzolo R; Zegarra-Moran O; Galietta LJ
Mol Pharmacol; 2005 Dec; 68(6):1736-46. PubMed ID: 16150931
[TBL] [Abstract][Full Text] [Related]
16. Cystic Fibrosis: Proteostatic correctors of CFTR trafficking and alternative therapeutic targets.
Hanrahan JW; Sato Y; Carlile GW; Jansen G; Young JC; Thomas DY
Expert Opin Ther Targets; 2019 Aug; 23(8):711-724. PubMed ID: 31169041
[No Abstract] [Full Text] [Related]
17. Revertant mutants modify, but do not rescue, the gating defect of the cystic fibrosis mutant G551D-CFTR.
Xu Z; Pissarra LS; Farinha CM; Liu J; Cai Z; Thibodeau PH; Amaral MD; Sheppard DN
J Physiol; 2014 May; 592(9):1931-47. PubMed ID: 24591578
[TBL] [Abstract][Full Text] [Related]
18. Dual activity of aminoarylthiazoles on the trafficking and gating defects of the cystic fibrosis transmembrane conductance regulator chloride channel caused by cystic fibrosis mutations.
Pedemonte N; Tomati V; Sondo E; Caci E; Millo E; Armirotti A; Damonte G; Zegarra-Moran O; Galietta LJ
J Biol Chem; 2011 Apr; 286(17):15215-26. PubMed ID: 21383017
[TBL] [Abstract][Full Text] [Related]
19. An overview on chemical structures as ΔF508-CFTR correctors.
Spanò V; Montalbano A; Carbone A; Scudieri P; Galietta LJV; Barraja P
Eur J Med Chem; 2019 Oct; 180():430-448. PubMed ID: 31326599
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological Correction of Cystic Fibrosis: Molecular Mechanisms at the Plasma Membrane to Augment Mutant CFTR Function.
Arora K; Naren AP
Curr Drug Targets; 2016; 17(11):1275-81. PubMed ID: 26648081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]